133 related articles for article (PubMed ID: 32541088)
1. [Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases].
Fogarassy G; Fogarassyné Vathy Á; Kováts T; Hornyák L; Kenessey I; Veress G; Polgár C; Forster T
Orv Hetil; 2020 Jun; 161(26):1094-1102. PubMed ID: 32541088
[TBL] [Abstract][Full Text] [Related]
2. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Kásler M; Forster T
Int J Cardiol; 2019 Jun; 285():47-52. PubMed ID: 30905520
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
5. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin.
Qin A; Thompson CL; Silverman P
J Cancer Surviv; 2015 Jun; 9(2):252-9. PubMed ID: 25342090
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
9. Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.
Menna P; Salvatorelli E
Chemotherapy; 2017; 62(3):159-168. PubMed ID: 28122377
[TBL] [Abstract][Full Text] [Related]
10. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
12. [Acute cardiogenic postoperative edema after doxorubicin (adriamycin) chemotherapy].
Boulay G; Debaene B
Ann Fr Anesth Reanim; 1998; 17(1):43-6. PubMed ID: 9750682
[TBL] [Abstract][Full Text] [Related]
13. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
14. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
[TBL] [Abstract][Full Text] [Related]
15. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
16. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
Villani F; Comazzi R; Lacaita G; Guindani A; Genitoni V; Volonterio A; Brambilla MC
Med Oncol Tumor Pharmacother; 1985; 2(2):93-7. PubMed ID: 3932789
[TBL] [Abstract][Full Text] [Related]
17. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
18. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
Green DM; Grigoriev YA; Nan B; Takashima JR; Norkool PA; D'Angio GJ; Breslow NE
J Clin Oncol; 2001 Apr; 19(7):1926-34. PubMed ID: 11283124
[TBL] [Abstract][Full Text] [Related]
19. Preventing cancer therapy-related heart failure: the need for novel studies.
Fogarassy G; Vathy-Fogarassy Á; Kenessey I; Veress G; Polgár C; Forster T
J Cardiovasc Med (Hagerstown); 2021 Jun; 22(6):459-468. PubMed ID: 32941327
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
